Gene Therapy is fastest growing segment fueling the growth of Epidermolysis Bullosa Market

 The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3813.38 Mn or Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Epidermolysis bullosa is a group of inherited skin fragility disorders affecting the epidermis and mucous membranes. The disorder is characterized by easy blistering and shearing of the skin and mucous membranes in response to minor injury or trauma. There are no known cures for any type of epidermolysis bullosa. Gene therapy and cell-based therapies hold promise as future treatment options that may be able to cure this condition.

Market key trends:
Gene therapy is emerging as one of the promising treatments for epidermolysis bullosa. Traditionally, epidermolysis bullosa treatments focused on wound care and pain management. However, gene therapy aims to correct the underlying genetic defects causing blistering and tissue fragility. For example, Amryt Pharma is developing gene therapy treatment called APODF-101 which aims to introduce normal collagen XVII gene into patients' own skin cells, so their skin can produce functional collagen and heal naturally. Successful developments and regulatory approvals of such gene therapies in the coming years will significantly drive the growth of epidermolysis bullosa market during the forecast period.

Segment Analysis
The global epidermolysis bullosa market is segmented into dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and dominant dystrophic epidermolysis bullosa. The dominant sub-segment is dystrophic epidermolysis bullosa, which accounts for nearly 40% market share, owing to the high prevalence of dystrophic epidermolysis bullosa condition.

Key Takeaways
The Global Epidermolysis Bullosa Market Size is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing R&D investment by key players for developing novel treatment options.

Regional analysis
North America is expected to dominate the global epidermolysis bullosa market over the forecast period. This is attributed to the growing prevalence of epidermolysis bullosa and presence of developed healthcare infrastructure and availability of reimbursement policies in the region. Europe is also expected to hold a significant market share due to increasing funding from governmental and private bodies for rare disease research.

Key players
Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma holds a major share of the market due to its commercialized product Filsuvez, indicated for treatment of dystrophic epidermolysis bullosa.

 

Read more: https://www.ukwebwire.com/epidermolysis-bullosa-market-share-analysis/